A Retrospective Study on Extranodal DLBCL
NCT06549361 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5023
Last updated 2024-08-12
Summary
The aim of this study is to prospectively collect clinical information of patients with extranodal DLBCL, assess the effectiveness of treatment for extranodal DLBCL in the real world, and explore the optimal treatment strategies in real-world populations.
Conditions
- Lymphoma
- Extranodal Lymphoma
- Diffuse Large B Cell Lymphoma
Interventions
- OTHER
-
No interventions need to be specified for this study
No interventions need to be specified for this study
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-01
- Primary Completion
- 2023-07-01
- Completion
- 2023-09-01
Countries
- China
Study Locations
More Related Trials
-
Decitabine and Anti-PD-1 in R/R DLBCL
NCT05816746 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase I/II Study of Diffuse Large B-cell Lymphoma
NCT04856137 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910 ·Status: ACTIVE_NOT_RECRUITING
-
Biomarker Guided Treatment in DLBCL
NCT04025593 ·Status: UNKNOWN ·Phase: PHASE2
-
PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT
NCT04799314 ·Status: UNKNOWN ·Phase: PHASE3
-
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
NCT07065344 ·Status: NOT_YET_RECRUITING
-
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT00568815 ·Status: COMPLETED ·Phase: PHASE2
-
Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05318391 ·Status: COMPLETED
-
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
NCT05874778 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
NCT07310186 ·Status: NOT_YET_RECRUITING
-
Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
NCT04697160 ·Status: COMPLETED
-
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05348213 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
NCT05267054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
NCT05459571 ·Status: COMPLETED ·Phase: PHASE2
-
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
NCT06669143 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
NCT06045585 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
NCT05444322 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
NCT03715296 ·Status: UNKNOWN
-
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
NCT05700149 ·Status: RECRUITING
-
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443 ·Status: COMPLETED
-
CT-011 MAb in DLBCL Patients Following ASCT
NCT00532259 ·Status: COMPLETED ·Phase: PHASE2
-
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05189782 ·Status: UNKNOWN
-
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
NCT04923789 ·Status: UNKNOWN